Inhibikase Therapeutics

Forecast & Rating9 analysts currently cover Inhibikase Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $6.00, about 157.5% upside from the current price of $2.33. Price targets range from $3.00 to $8.00 — a wide spread, showing clear disagreement over just how much Inhibikase Therapeutics can rise. For you, this means most professionals who study Inhibikase Therapeutics closely still see room for the stock to rise. Data as of Jul 13, 2026; for reference only and not investment advice.